Brand Institute Partners on Brand Name Development for FDA-Approved Biologic Medication for the Treatment of Cancer

Celltrion promotes health and welfare for all through the development of next-generation biopharmaceutical and small molecule pharmaceutical products.

Metadata
Provider: 
PR NewswirePR Newswire
Retrieved on: 
Wednesday, October 19, 2022
Information
Tags: 
Celltrion, HC, Health care, Review, EMA, Patient, Food and Drug Administration, Health Canada, WHO, Food, World, Brand Institute, Biosimilar, Health, European Medicines Agency, Safety, World Health Organization, American Medical Association, AMA, Bevacizumab, C.E.O, Approximation error, FDA, Name, Pharmaceutical industry
Geotags: 
FLORIDA, UNITED STATES
Organisation: 
BRAND INSTITUTE, INC.
Summary
Key Points: 
  • Celltrion promotes health and welfare for all through the development of next-generation biopharmaceutical and small molecule pharmaceutical products.
  • "The entire Brand Institute and Drug Safety Institute Team congratulates Celltrion Healthcare on the FDA approval of VEGZELMA," said Brand Institute's Chairman and C.E.O., James L. Dettore.
  • About Brand Institute and our wholly owned regulatory subsidiary, Drug Safety Institute
    Brand Institute is the global leader in pharmaceutical and healthcare-related name development, with a portfolio of over 4,000 marketed healthcare brand names, 1,300 USAN/INN nonproprietary names for 1,200 clients.
  • The company partners on over 75% of pharmaceutical brand and nonproprietary name approvals globally every year with healthcare manufacturers.


Brand Institute Partners on Brand Name Development for FDA-Approved Biologic Medication for the Treatment of Cancer

MIAMI, Oct. 19, 2022 /PRNewswire/ -- Brand Institute is proud to announce its work with Celltrion Healthcare in developing the brand name VEGZELMA®, which was approved by the FDA on September 27, 2022.

As a product, VEGZELMA® (bevacizumab-adcd) is the fourth bevacizumab biosimilar currently approved in the United States. VEGZELMA® is indicated for the treatment of patients with:

  • Metastatic colorectal cancer
  • Recurrent or metastatic non-squamous non-small cell lung cancer
  • Recurrent glioblastoma
  • Metastatic renal cell carcinoma
  • Persistent, recurrent, or metastatic cervical cancer
  • Epithelial ovarian, fallopian tube, or primary peritoneal cancer

Celltrion Healthcare is a global biopharmaceutical company based in South Korea that produces biopharmaceuticals in collaboration with its global partners and builds distribution channels for pharmaceuticals. Celltrion promotes health and welfare for all through the development of next-generation biopharmaceutical and small molecule pharmaceutical products.

"The entire Brand Institute and Drug Safety Institute Team congratulates Celltrion Healthcare on the FDA approval of VEGZELMA," said Brand Institute's Chairman and C.E.O., James L. Dettore.

About Brand Institute and our wholly owned regulatory subsidiary, Drug Safety Institute

Brand Institute is the global leader in pharmaceutical and healthcare-related name development, with a portfolio of over 4,000 marketed healthcare brand names, 1,300 USAN/INN nonproprietary names for 1,200 clients. The company partners on over 75% of pharmaceutical brand and nonproprietary name approvals globally every year with healthcare manufacturers.

Drug Safety Institute is composed of former naming regulatory officials from global government health agencies, including Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada (HC), American Medical Association (AMA), and the World Health Organization (WHO). These regulatory experts co-authored the name review guidelines while with their respective agencies, with many responsible for ultimately approving (or rejecting) brand name applications. Now working for a private company, these professionals provide Brand Institute's clients with industry-leading guidance pertaining to drug name safety (i.e., preventing medication errors), packaging, and labeling.

Contact:
James Dettore
Chairman & C.E.O.
[email protected]
www.brandinstitute.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/brand-institute-partners-on-brand-name-development-for-fda-approved-biologic-medication-for-the-treatment-of-cancer-301652750.html

SOURCE Brand Institute, Inc.

Copyright: 
2022 PR Newswire. All Rights Reserved.